Is controlling production of Advanced Glycation End-products (AGEs) a promising therapeutic strategy for management of diabetes and other diseases related to immune activation and inflammation, or is this just one of many pathological phenomena that accompany and worsen chronic illness?

We see this as a downstream consequence of chronic viral infection, and one of many. So dealing with this alone will not be a primary and valuable healing strategy, but a potential useful adjunct to minimize AGEs being produced or to be better eliminated.